JonesTrading analyst Prakhar Agrawal maintained a Buy rating on Phathom Pharmaceuticals (PHAT) today and set a price target of $58.00. The company’s shares closed last Tuesday at $32.97, close to its 52-week low of $28.10.
According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -7.2% and a 16.7% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Aldeyra Therapeutics, and Ocuphire Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $60.25 average price target, representing an 88.0% upside. In a report issued on April 30, Evercore ISI also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.54 and a one-year low of $28.10. Currently, Phathom Pharmaceuticals has an average volume of 98.51K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.